

GLAXOSMITHKLINE PLC  
Form 6-K  
May 21, 2008

**FORM 6-K**

**SECURITIES AND EXCHANGE COMMISSION  
Washington D.C. 20549**

**Report of Foreign Issuer**

**Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934**

For period ending May 21, 2008

**GlaxoSmithKline plc**  
(Name of registrant)

**980 Great West Road, Brentford, Middlesex, TW8 9GS**  
(Address of principal executive offices)

Indicate by check mark whether the registrant files or  
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F  Form 40-F

--

Indicate by check mark whether the registrant by furnishing the  
information contained in this Form is also thereby furnishing the  
information to the Commission pursuant to Rule 12g3-2(b) under the  
Securities Exchange Act of 1934.

Yes No

--

**Issued – Wednesday 21 May 2008, London - LSE Announcement**

**GlaxoSmithKline plc - Results of AGM**

GlaxoSmithKline (GSK) announces that at today's Annual General Meeting all resolutions, including those electing and re-electing Board members, were passed by shareholders.

## GlaxoSmithKline Annual General Meeting Poll Results

The following table shows the votes cast for each resolution:

	<b>Resolution</b>	<b>Total votes for *</b>	<b>%</b>	<b>Total votes against</b>	<b>%</b>	<b>Total votes cast</b>	<b>Votes withheld **</b>
1	Adoption of Financial Statements	3,749,614,298	95.18	189,859,453	4.82	3,939,473,751	9,410,864
2	Approval of the Remuneration Report	2,423,411,670	85.89	398,271,204	14.11	2,821,682,874	1,127,201,561
3	Election of Mr Andrew Witty	3,877,718,934	99.23	29,969,659	0.77	3,907,688,593	41,195,842
4	Election of Mr Christopher Viehbacher	3,849,501,839	99.49	19,772,868	0.51	3,869,274,707	79,609,728
5	Election of Professor Sir Roy Anderson	3,909,528,117	99.82	7,050,023	0.18	3,916,578,140	32,306,295
6	Re-election of Sir Christopher Gent	3,810,072,560	98.08	74,773,259	1.92	3,884,845,819	64,038,616
7	Re-election of Sir Ian Prosser	3,907,565,196	99.77	9,050,718	0.23	3,916,615,914	32,268,521
8	Re-election of Dr Ronaldo Schmitz	3,899,485,674	99.56	17,139,141	0.44	3,916,624,815	32,259,620
9	Re-appointment of Auditors	3,877,708,481	99.54	17,936,334	0.46	3,895,644,815	53,239,620
10	Remuneration of Auditors	3,913,134,400	99.69	12,121,289	0.31	3,925,255,689	23,628,746
11	To authorise the company to make donations to Political Organisations & incur Political Expenditure	3,764,947,848	97.09	112,911,635	2.91	3,877,859,483	71,024,952
12	Authority to allot shares	3,877,961,825	98.44	61,623,083	1.56	3,939,584,908	9,299,527
13	Disapplication of pre-emption rights***	3,891,091,851	98.82	46,291,865	1.18	3,937,383,716	11,500,719
14	Authority for the Company to	3,871,222,137	98.23	69,853,695	1.77	3,941,075,832	7,808,603

	purchase its own shares ***						
	Adopt new						
15	Articles of Association ***	3,919,473,970	99.55	17,602,044	0.45	3,937,076,014	11,808,421

**Notes:**

\* Includes discretionary votes.

\*\* A vote withheld is not a vote in law and is not counted in the calculation of the proportion of votes "For" or "Against" a resolution.

\*\*\* Indicates Special Resolutions requiring a 75% majority

The following table provides further relevant information:

	<b>GlaxoSmithKline's Eighth AGM (2008)</b>	<b>GlaxoSmithKline's Seventh AGM (2007)</b>
Issued share capital (excluding Treasury Shares)	5 , 352 , 175 , 102	5,725,158,425
Total votes cast and votes withheld lodged as a % of GSK's issued share capital (excluding Treasury Shares)	73.78%	73.68%
Total shareholder population	172,581	180,486
Total number of proxies lodged	12,896	14,357
% of shareholders who lodged proxies	7.47%	7.95%
Number of shareholders, corporate representatives and proxies who attended the AGM	266	276

**S M Bicknell**  
**Company Secretary**  
**21 May 2008**

These results will shortly be available on the Company's website [www.gsk.com](http://www.gsk.com).

Enquiries:	UK Media	Philip Thomson	(020) 8047 5502
		Alice Hunt	(020) 8047 5502
		Gwenan White	(020) 8047 5502

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

US Media	Nancy Pekarek	(215) 751 7709
	Mary Anne Rhyne	(919) 483 2839
European Analyst / Investor	David Mawdsley	(020) 8047 5564
	Sally Ferguson	(020) 8047 5543
	Gary Davies	(020) 8047 5503
US Analyst / Investor	Frank Murdolo	(215) 751 7002
	Tom Curry	(215) 751 5419

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

**GlaxoSmithKline plc**  
(Registrant)

Date: May 21, 2008

By: VICTORIA WHYTE

-----  
Victoria Whyte  
Authorised Signatory for and on  
behalf of GlaxoSmithKline plc